FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
EyePoint's Duravyu fails primary endpoint in second wet AMD trial
Tweet Send to a Friend
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its investigational treatment DURAVYU (vorolanib intravitreal insert) failed to meet the primary endpoint in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
